Professor Dania Cioni graduate in Medicine and Surgery from University of Pisa in 1997. She is now Associate Professor at the University of Pisa, Division of Radiology, Department of Surgical, Medical, Molecular Pathology and Emergency Medicine.  According to the SCOPUS database, citations of her publications currently number in excess of 3,500, for an h-index of 29. Professor Cioni spent most of her scientific research carrier in the field of  liver lesions with the following activities:

• Ultrasound, ultrasound contrast agent, new ultrasound 3D software in the study of liver lesions and arterial vessels
• Optimization of computed tomography protocols for the study of liver tumors and in their evaluation after treatments
• Interventional radiology in lung and liver tumors
• New magnetic resonance imaging techniques and contrast agents for the study of liver tumors and in their evaluation after treatments
• Radiomics of liver lesions

HONOURS AND MEMBERSHIPS

• Member of the European Society of Radiology (ESR),
• Member of the European Society of Oncologic Imaging,
• Member of the Italian Society of Radiology,
• Member of the Italian Section of Oncologic Imaging.

RESEARCH PROJECTS

• PRIN 2005 Development of a database for CT colonoscopy examinations and comparison of diagnostic accuracy between 2d and 3D visualization systems
• PRA 2017 Contrast-enhanced and 3D ultasound evaluation of carotid artery disease
• PRA 2020 Hepatic/systemic inflammation, leaky-gut and vascular function biomarkers in fatty liver disease
• PRIN 2021 The Carotid Artery Multi-modality imaging Project-dietary Intervention trial (CAMP-Intervention)
• Member of the study’s research team CHAIMELEON “Accelerating the lab to market transition of AI tools for cancer management” financed by the European Union;
• Member of the study’s research team EuCanImage “A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology” financed by the European Union;
• Member of the study’s research team Procancer-I “An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum” financed by the European Union;
• Member of the study’s research team PRIMAGE (PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers) financed by the European Union through Horizon 2020;
• Collaboration in an Italian multicenter study on renal tumors.